Search results
Results from the WOW.Com Content Network
Chikungunya is an infection caused by the Alphavirus chikungunya (CHIKV). [7] [8] [5] The disease was first identified in 1952 in Tanzania and named based on the Kimakonde words for "to become contorted". [5] Symptoms include fever and joint pain. [4] These typically occur two to twelve days after exposure. [5]
In May 2009 the provincial hospital in Trang Province prematurely delivered a 2.7 kg (6 pounds) male baby from his chikungunya-infected mother in the hopes of preventing mother-foetus virus transmission. After a cesarean delivery, the physicians discovered that he had also been infected with the chikungunya virus, and put him under intensive care.
For premium support please call: 800-290-4726 more ways to reach us
Laboratory blood tests can identify evidence of chikungunya or other similar viruses such as dengue and Zika. [34] Blood test may confirm the presence of IgM and IgG anti-chikungunya antibodies. IgM antibodies are highest 3 to 5 weeks after the beginning of symptoms and will continue be present for about 2 months. [34]
Chikungunya is rarely fatal. Symptoms are generally self-limiting and last for 2–3 days. The disease shares some clinical signs with dengue and zika, and can be misdiagnosed in areas where they are common. [88] Here is the Clinical features of Chikungunya virus infections compared with dengue virus infections. [89]
Scabies (also sometimes known as the seven-year itch) is a contagious human skin infestation by the tiny (0.2–0.45 mm) mite Sarcoptes scabiei, variety hominis. The word is from Latin: scabere, lit. 'to scratch'. The most common symptoms are severe itchiness and a pimple -like rash. Occasionally, tiny burrows may appear on the skin. In a first-ever infection, the infected person usually ...
Human infectious diseases may be characterized by their case fatality rate (CFR), the proportion of people diagnosed with a disease who die from it (cf. mortality rate).It should not be confused with the infection fatality rate (IFR), the estimated proportion of people infected by a disease-causing agent, including asymptomatic and undiagnosed infections, who die from the disease.
Even beyond Keytruda, Davis has diversified Merck’s pipeline by tripling over the last three years the number of drug candidates in late-phase development, which represents over $50 billion in ...